What is required when study subjects are informed of increased risks due to missed drug administration?

When study subjects are informed of increased risks due to missed drug administration, close monitoring of the subject is necessary. This approach ensures that any adverse effects or complications arising from the missed doses can be promptly identified and addressed. Close monitoring helps to protect the health and safety of participants by allowing researchers to intervene if necessary, thereby minimizing potential harm.

Additionally, this practice aligns with ethical obligations in research to safeguard the well-being of participants. Continuous observation also helps researchers gather important data on the effects of the missed administration, potentially informing future studies or adjustments to the protocol.

In contrast, the other options do not provide the same level of participant protection or data integrity. Routine examination alone may not be sufficient to detect immediate issues, while no follow-up could result in serious health risks going unnoticed. Immediate withdrawal from the study, although it could protect the subject, might not allow for collection of critical data related to the impact of the missed drug administration. Hence, close monitoring represents a balanced and ethically responsible response to increased risk scenarios in research settings.